More consolidation didn't boost sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.
Jerry Cacciotti
Advertisement
Articles by Jerry Cacciotti
Pharmaceutical Executive
The disease profiles pharma companies pursue should shape the business models that enable them to grow.
Advertisement
Latest Updated Articles
Pharm Exec 50: Growth from the Bottom UpMay 1st 2012
Pharma's Next Top Model: Slimmer Business ModelsMarch 1st 2006
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
5